-- 加拿大国家银行周三将Timbercreek Financial (TF.TO) 的目标股价下调1美元至7美元，此前该公司公布了喜忧参半的第一季度业绩。 分析师Jaeme Gloyn指出，Timbercreek的盈利低于预期0.13美元，而加拿大国家银行的预期为0.16美元。Gloyn维持对该公司“与行业持平”的评级。他指出，Timbercreek正在努力应对“大量”不良贷款组合（随着贷款的解决，信贷损失持续上升）以及低利率环境（导致净利息收入低于预期）。 尽管如此，Gloyn补充道，Timbercreek的贷款发放量再次强劲增长，凸显了其稳健的业务储备，以及稳定的可分配收入，该收入超过了普通股股息。
Price: $6.63, Change: $-0.02, Percent Change: -0.30%
Aptiv (APTV) stock sell-off post Q1 results was unwarranted and likely driven by the lower-than-expected Q2 guide and rising cost pressures with 2026 more back-half weighted that appears like a steep ramp, UBS said in a Wednesday research report.While Q2 is impacted by "stranded cost" and Ford Motor (F) volume timing, H2 ramp looks more achievable than optics suggest amid positive developments in China and the non-auto segments, analysts wrote.The company expects positive growth from China in Q2, driven by new programs and normalization of production at key customer, the brokerage stated.Commodity headwinds should abate in H2 as recoveries lag, UBS said.The brokerage said it reiterated its buy rating on the stock and price target of $80 per share.Aptiv shares were up 4% in Wednesday trading.Price: $56.47, Change: $+1.64, Percent Change: +2.99%
Price: $15.79, Change: $-4.34, Percent Change: -21.55%
Ocular Therapeutix (OCUL) is moving closer to a potential US Food and Drug Administration filing for axpaxli, its long-acting treatment for wet age-related macular degeneration, as regulators begin formal discussions on a single-trial approval path, RBC Capital Markets said Tuesday in a report.Management said talks with the FDA are now ongoing, raising the possibility of submitting an application based on the company's successful pivotal study, rather than waiting for a second trial that is due to read out in early 2027, RBC said.The company plans to provide additional regulatory and program updates at an investor day on June 17, RBC said.Ocular continues to target a potential 2027 launch for axpaxli under a single-trial filing strategy, and RBC reiterated its view that the drug has a "positive benefit/risk profile."RBC maintained its rating of outperform, speculative risk, on Ocular stock with a $30 price target.Price: $9.84, Change: $+0.13, Percent Change: +1.29%